Merus N.V. (MRUS)

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Merus...

Genmab A/S (NASDAQ: GMAB) on Monday agreed to acquire Merus N.V. (NASDAQ: MRUS) with its late-stage asset petosemtamab, which is in Phase 3 development, for $97 per share in an all-cash transaction re...

Genmab will acquire Merus in an all-cash transaction worth around $8 billion.

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Merus N.V. (NASDAQ: MRUS) to Genmab A/S for $97.00 per share is fair to Merus shareholder...

Merus agreed to be bought for a 41% premium, months after a positive trial of a cancer drug.

Denmark's Genmab has agreed to acquire Merus NV, a Nasdaq-listed Dutch biotechnology company, in an all-cash transaction valued at $8 billion, the companies announced on Monday. The deal marks a signi...

Denmark's Genmab has agreed to acquire Merus NV , a Nasdaq-listed Dutch biotech firm developing a head-and-neck cancer drug, for $8 billion in cash, the two companies said on Monday.

COPENHAGEN, Denmark & UTRECHT, Netherlands--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and Merus N.V. (Nasdaq: MRUS) announced today that they have entered into a transaction agreement pursuant to whi...

Merus N.V. (MRUS) came out with a quarterly loss of $2.23 per share versus the Zacks Consensus Estimate of a loss of $1.17. This compares to a loss of $0.81 per share a year ago.

NEW YORK--(BUSINESS WIRE)--Merus Global Investments (“Merus”), a multi-strategy investment partnership, today unveiled its refreshed website and announced a series of senior promotions and strategic a...